Hematologic Malignancy
Nasal Type Extranodal NK/T-Cell Lymphoma
CI-CAN-00006107Explore in graph →
Hematologic25 active trials
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006107Explore in graph →
Clinical trials
146 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (21)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04414163 | A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type | active not recruiting | Phase 2 | 23 | ImmuneOncia Therapeutics Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07791615 | A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma | not yet recruiting | Phase 2 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 28, 2026 |
| clinicaltrials |
| NCT05254899 | A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)(CLCG-2102) | completed | Phase 2 | 54 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT00336063 | Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 4 | Aug 19, 2026 | clinicaltrials |
| NCT07768943 | GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma | not yet recruiting | Phase 2 | 620 | Fudan UniversityOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07678229 | BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL(BRIDGE-NK) | recruiting | Phase 3 | 150 | Rong TaoOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07727083 | Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases(EBV-T/NK Cohor) | recruiting | — | 1,500 | Rong TaoOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | suspended | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07502768 | Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma(EpiRev-NKT) | recruiting | Phase 1 / Phase 2 | 107 | Rong TaoOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT01787409 | Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency | active not recruiting | N/A | 565 | Mayo ClinicOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT02232516 | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | completed | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07639879 | TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma | not yet recruiting | Phase 3 | 180 | Tarapeutics Science Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05700448 | Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma | not yet recruiting | Phase 3 | 150 | CStone PharmaceuticalsINDUSTRY | 0 | May 27, 2026 | clinicaltrials |
| NCT07554482 | Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma | not yet recruiting | Phase 2 | 34 | Beijing Tongren HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07525466 | Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) | recruiting | Phase 1 / Phase 2 | 25 | Beijing Tongren HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04417166 | Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma | active not recruiting | Phase 2 | 30 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07457177 | Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL | not yet recruiting | Phase 2 | 40 | LIANG WANGOTHER | 0 | Mar 9, 2026 | clinicaltrials |
| NCT07385989 | Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma | not yet recruiting | Phase 2 | 40 | WEI XUOTHER | 0 | Feb 4, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06069830 | PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma(ENKTL) | recruiting | N/A | 89 | Ruijin HospitalOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07276698 | Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma | not yet recruiting | Phase 2 | 39 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Dec 11, 2025 | clinicaltrials |
| NCT07276737 | Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma | not yet recruiting | Phase 2 | 37 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Dec 11, 2025 | clinicaltrials |
| NCT07000617 | A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma | recruiting | Phase 2 | 57 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06953739 | A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL. | not yet recruiting | Phase 3 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 1, 2025 | clinicaltrials |
| NCT06863441 | The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma | not yet recruiting | — | 50 | Ruijin HospitalOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06824883 | Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma | recruiting | Phase 2 | 49 | Peking Union Medical College HospitalOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT06747299 | The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study | not yet recruiting | — | 200 | Ruijin HospitalOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03493451 | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms | completed | Phase 2 | 77 | BeiGeneINDUSTRY | 5 | Oct 26, 2024 | clinicaltrials |
| NCT05662540 | PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma | recruiting | N/A | 40 | Ruijin HospitalOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06573138 | Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL | not yet recruiting | Phase 2 | 18 | Ruijin HospitalOTHER | 0 | Aug 27, 2024 | clinicaltrials |
| NCT06406556 | Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL(ENKTL) | unknown | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT03246750 | B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma | completed | Phase 1 / Phase 2 | 34 | The Thai Lymphoma Study GroupOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT02168140 | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | completed | Phase 1 | 16 | Wake Forest University Health SciencesOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | terminated | Phase 1 | 3 | Stanford UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT01523223 | Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies | completed | Phase 1 | 16 | Robert LowskyOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT01336920 | Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | completed | Phase 1 | 15 | University of NebraskaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | terminated | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05941156 | Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia | unknown | Phase 2 | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT04554511 | Prognostic Nomogram of Extranodal NK/T-cell Lymphoma | unknown | — | 1,000 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05907447 | A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types | unknown | — | 10,000 | Ruijin HospitalOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03999658 | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies | withdrawn | Phase 2 | 0 | Sorrento Therapeutics, Inc.INDUSTRY | 0 | May 1, 2023 | clinicaltrials |
| NCT05833893 | Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma | recruiting | Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT04526834 | Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma(CERTAIN) | active not recruiting | Phase 1 | 21 | Tessa TherapeuticsINDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05131438 | An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL) | no longer available | — | — | EQRx International, Inc.INDUSTRY | 1 | Mar 27, 2023 | clinicaltrials |
| NCT05774028 | Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma | unknown | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 17, 2023 | clinicaltrials |
| NCT03049449 | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Jan 18, 2023 | clinicaltrials |
| NCT02859402 | Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas(RRTCLAlloSCT) | recruiting | Phase 2 | 34 | Keimyung University Dongsan Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05426824 | The Whole-course Management of Pegaspargase in ENKTL | unknown | N/A | 72 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 22, 2022 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials